A Phase 1 interventional study of EP-104IAR and Vehicle in Osteoarthritis, Knee, sponsored by Eupraxia Pharmaceuticals Inc.. Completed at 3 sites in Canada. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-09-01.
Sponsored by Eupraxia Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 40 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 116th largest by enrollment of the 160 interventional ones that give a count, is one of 6 that started in 2016, is one of 2 in phase 1, and was the 70th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 7 more countries
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 40–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 25 · Phase 4 10
First in 1999; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 63 across the 160 interventional studies, 48 across the 10 observational. Of the 106 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 171 have an industry lead sponsor. The 10 most frequent:
Eupraxia Pharmaceuticals Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Eupraxia Pharmaceuticals Inc. has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
14 of the studies in Osteoarthritis, Knee with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283889University of CalgaryGenicular Radiofrequency Ablation Following Total Knee Arthroplasty | 2026-12 |
| NCT04378049McMaster UniversityRobot-Assisted Partial Knee Replacement Versus Standard Total Knee Replacement | 2026-12 |
| NCT01674816Centre hospitalier de l'Université de Montréal (CHUM)Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration | 2026-12-01 |
| NCT06166628David ClinkardGenicular Artery Embolization vs Nerve Ablation Intervention (GENI) for Knee Osteoarthritis | 2026-12-01 |
| NCT06195423University of British ColumbiaStopping OsteoARthritis After an ACL Tear | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to understand the pharmacokinetics of EP-104IAR and to determine whether it is safe to use in patients with osteoarthritis (OA) of the knee. The study will also provide some preliminary insights into whether the experimental treatment reduces pain in the knee.
Osteoarthritis is the most common joint disease, affecting over 20 million people in the US alone. Currently, pain treatments that are injected directly into the knee often work for only a short time and may also have side effects within the rest of the body. The experimental treatment is a steroid that is in the same family of drugs as the most common current injectable treatments for knee osteoarthritis. For this study, the drug is coated with a polymer intended to prolong the time it stays inside the knee and lessen potential side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15mg EP-104IAR in 4 mL carrier fluid
Drug: EP-104IAR
4 mL carrier fluid
Drug: Vehicle
Single, ultrasound-guided injection of EP-104IAR into the knee
Single, ultrasound-guided injection of vehicle placebo into the knee
Peak Plasma Concentration (Cmax) of fluticasone propionate
Time frame: Up to 42 weeks
Fluticasone propionate concentrations in synovial fluid
Time frame: Up to 30 weeks
Area under the plasma concentration versus time curve (AUC) of fluticasone propionate
Time frame: 12 weeks
Incidence of treatment-emergent adverse events
Time frame: Up to 42 weeks
Change from baseline in clinical laboratory parameters: hematology, chemistry (including cortisol) and urinalysis
Time frame: Up to 42 weeks
Time to baseline pain in patient-reported Pain Numerical Rating Scale for Index knee
Time frame: Weekly up to 42 weeks
Change from baseline in patient-reported Pain Numerical Rating Scale for Index knee
Time frame: Weekly up to 42 weeks
Change from baseline in patient-reported Global Assessment of Arthritis
Time frame: Up to 42 weeks
Change from baseline in patient-reported Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Time frame: Up to 42 weeks
Change from baseline in patient-reported Short Form - 36 quality of life scores
Time frame: Up to 42 weeks
Change from baseline in Physician's Global Assessment of Arthritis
Time frame: Up to 42 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2016 to primary completion in Dec 2017, 20 months.
Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 20 months is above that.
Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eupraxia Pharmaceuticals Inc.